Latest News

• share
• favorite_border

For 2.7 million Americans with epilepsy, seizures are not the only concern. People with epilepsy frequently face mood and behavior challenges and side effects from their medications, such as sleep and cognition problems. And, in many instances, these issues are not getting the attention warranted during visits with neurologists, according to a study supported by Ortho-McNeil Neurologics®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

• share
• favorite_border

Employees with epilepsy cost healthcare insurers and employers significantly more than those without the condition, according to findings from two studies presented here today at the American Academy of Neurology (AAN) Annual Meeting.

• share
• favorite_border

While the number of Americans registered as organ and tissue donors is rising, the registry still only includes 38 percent of licensed drivers, according to a report card issued by Donate Life America this year. Yet, according to a new survey of Americans, 72 percent of people want their decision to donate honored, even if their family disagrees.

• share
• favorite_border

Leading epilepsy specialists met today at the American Epilepsy Society annual meeting in Seattle to unveil a recently published consensus report that proposes minimum standards of care for diagnosing, treating and monitoring epilepsy. Primary among these is the need for a detailed medical history, neurological examination, discussions with caregivers and diagnostic tests to make a diagnosis, as well as the need to weigh seizure control, side effects and long-term safety when making treatment decisions.

• share
• favorite_border

In celebration of National Epilepsy Awareness Month, Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, and the Epilepsy Foundation today announced the winners of the 2008 Expressions of Courage art contest. Now in its sixth year, the contest recognizes creativity and the ability to demonstrate feelings of living with epilepsy through art.

• share
• favorite_border

Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the fourth annual Astellas Ride of a Lifetime contest. Launched in April 2008, the Astellas Ride of a Lifetime contest asked organ transplant recipients to write an essay explaining how their transplant experience transformed their life.

• share
• favorite_border

At work, at home and in relationships, new survey findings point to ADHD challenges in adults.

• share
• favorite_border

The Expressions of Courage national art contest, sponsored by ORTHO-McNEIL NEUROLOGICS in partnership with the Epilepsy Foundation, provides people with epilepsy the opportunity to showcase their talents and their perspectives of the world around them through art.

• share
• favorite_border

On the heels of the National Walk for Epilepsy, advocates announced their recommendations in response to a new national survey uncovering challenges facing the epilepsy community. Challenges include gaps in patient-physician communication around medication-related side effects and low public awareness of epilepsy.

• share
• favorite_border

With recent news about "super bugs," you may wonder if antibiotics are still effective, and whether they will work for you when you need them. You're not alone - there is a lot of confusion about antibiotics - what they do and don't treat, and why they sometimes stop working. It is important to know that antibiotics are effective only if they are prescribed and taken correctly.

• share
• favorite_border

Data demonstrated that rotigotine improved symptoms associated with early-stage PD. Data from a second Phase III trial showed rotigotine also reduced "off" time and increased "on" time without troublesome dyskinesias in patients with advanced-stage PD already taking levodopa.

• share
• favorite_border

Survey shows physicians sensitive to impact of overactive bladder, but many do not actively screen for it.

• share
• favorite_border

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has granted marketing clearance for Reyataz (tm), an azapeptide protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

• share
• favorite_border

Bristol-Myers Squibb Company presented resistance data today at a medical meeting in Boston from several Phase II and Phase III studies of atazanavir, an investigational protease inhibitor under development for the treatment of HIV/AIDS.

• share
• favorite_border

The U.S. Food and Drug Administration has approved Levaquin (r) (levofloxacin) Tablets/Injection and Levaquin (r) (levofloxacin in 5% dextrose) Injection 750mg for the treatment of nosocomial (hospital-acquired) pneumonia.

• share
• favorite_border

ORTHO TRI-CYCLEN(r) LO Tablets, the new low- dose version of the most prescribed birth control pill, is now available by prescription. Recently approved by the U.S. Food and Drug Administration, ORTHO TRI-CYCLEN LO contains a combination of hormones -- 25 micrograms (mcg) of estrogen and the progestin, norgestimate -- that offers excellent efficacy, tolerability and cycle control.

• share
• favorite_border

TRUST 6, the largest, longest-running and broadest surveillance of resistance patterns, shows that resistance to levofloxacin is relatively rare in the treatment of S. pneumoniae and remains low (0.9%) compared to other antibiotic classes.

• share
• favorite_border

The U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive, Ortho Tri-Cyclen(R) Lo (norgestimate/ethinyl estradiol) Tablets for the prevention of pregnancy. Ortho Tri-Cyclen Lo will be available by prescription in the fall.

• share
• favorite_border

Phase III study data show that the investigational once-daily extended release formulation has similar virologic activity to the currently approved immediate release ZERIT through 48 weeks of HIV treatment. This extended release formulation of ZERIT may offer patients the efficacy and durability of immediate release ZERIT with the convenience of simplified dosing.

• share
• favorite_border

The results from this study support the use of SUSTIVA in protease inhibitor sparing regimens for patients with low CD4 counts, high viral loads and opportunistic infections.